Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-79
SponsorUniversity of Rochester
About this trial
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).
Eligibility criteria
Qualifiers
Female sex, age 18-79 years.
Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
Baseline LVEF ≥ 55 % by 2-D echocardiography.
Ability to provide informed consent.
Disqualifiers
Prior HF, myocardial infarction, or cardiomyopathy.
Atrial fibrillation or significant valvular heart disease.
Cumulative anthracycline dose ≥ 250 mg/m².
Pregnancy or lactation.
Trial design
Treatments tested in this trial
- Echocardiogram
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov